Nasdaq · Healthcare
Sanara MedTech Inc. (SMTI)
As-reported financials and recent SEC filings for Sanara MedTech Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$103.1M
Net income
$-37.6M
Net margin
-36.4%
Diluted EPS
$-4.36
ROE
-633.5%
P/E (TTM)
—
Market cap
—
Debt / equity
7.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $103.1M | $86.7M | $65.0M | $45.8M | $24.1M |
| Gross profit | — | $78.5M | $57.1M | $39.5M | $21.8M |
| Operating income | $7.3M | $1.3M | $-4.2M | $-12.5M | $-7.4M |
| Net income | $-37.6M | $-9.7M | $-4.3M | $-7.9M | $-7.9M |
| Diluted EPS | $-4.36 | $-1.14 | $-0.52 | $-1.00 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-09
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Largest Healthcare peers
Go deeper on SMTI
Search Sanara MedTech Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.